Epidemiological changes in Eisenmenger syndrome in the Nordic region in 1977-2012Show others and affiliations
2017 (English)In: Heart, ISSN 1355-6037, E-ISSN 1468-201X, Vol. 103, no 17, p. 1353-1358Article in journal (Refereed) Published
Abstract [en]
OBJECTIVE: Improved diagnostic tools, timely closure of the shunt and a better understanding of the complexity of Eisenmenger syndrome (ES) have led to improved care and treatment in tertiary centres. These may have decreased the incidence of ES and improved survival of patients with ES, although evidence is still lacking. The aim of this study was to investigate temporal changes in incidence, prevalence and mortality in patients with ES for 35 years in the Nordic region.
METHODS: This was a retrospective population-based study including 714 patients with ES. Survival analysis was performed based on all-cause mortality and accounting for immortal time bias.
RESULTS: The incidence of ES decreased from 2.5/million inhabitants/year in 1977 to 0.2/million inhabitants/year in 2012. Correspondingly, prevalence decreased from 24.6 to 11.9/million inhabitants. The median survival was 38.4 years, with 20-year, 40-year and 60-year survival of 72.5%, 48.4%, and 21.3%, respectively. Complex lesions and Down syndrome were independently associated with worse survival (HR 2.2, p<0.001 and HR 1.8, p<0.001, respectively). Age at death increased from 27.7 years in the period from 1977 to 1992, to 46.3 years from July 2006 to 2012 (p<0.001).
CONCLUSIONS: The incidence and prevalence of ES in the Nordic region have decreased markedly during the last decades. Furthermore, the median age at death increased throughout the study period, indicating prolonged life expectancy in the ES population. However, increasing age represents decreased incidence, rather than improved survival. Nonetheless, longevity with ES is still shorter than in the background population.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2017. Vol. 103, no 17, p. 1353-1358
Keywords [en]
Eisenmenger syndrome, adult congenital heart disease, epidemiology, pulmonary arterial hypertension, survival
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:oru:diva-60907DOI: 10.1136/heartjnl-2016-310979ISI: 000407613900010PubMedID: 28450553Scopus ID: 2-s2.0-85027546882OAI: oai:DiVA.org:oru-60907DiVA, id: diva2:1142453
Note
Funding agencies:
Actelion Denmark (a branch of Actelion Pharmaceuticals in Sweden)
2017-09-192017-09-192020-12-01Bibliographically approved